TICKERNOMICS Sign up
Last Update: 2023-12-23 06:03:58
Medicenna Therapeutics Corp. ( MDNA ) https://www.medicenna.com
0.30USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Canada
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-27.38%
MDNA
SPY
30.72%
-92.77%
MDNA
SPY
112.82%
-53.56%
MDNA
SPY
201.04%
MDNA
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
21.24
2.22
0.14
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-2.04
0.00
1.22
-31.74
0.00
-0.13
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
13.0094
-66.54
-70.44
2.21
Other Earnings and Cash Flow Stats:
Medicenna Therapeutics Corp. ( MDNA ) Net Income TTM ($MM) is -9.14
Medicenna Therapeutics Corp. ( MDNA ) Operating Income TTM ($MM) is -17.95
Medicenna Therapeutics Corp. ( MDNA ) Owners' Earnings Annual ($MM) is 0.00
Medicenna Therapeutics Corp. ( MDNA ) Current Price to Owners' Earnings ratio is 0.00
Medicenna Therapeutics Corp. ( MDNA ) EBITDA TTM ($MM) is -17.94
Medicenna Therapeutics Corp. ( MDNA ) EBITDA Margin is 0.00%
Capital Allocation:
Medicenna Therapeutics Corp. ( MDNA ) has paid 0.00 dividends per share and bought back -6.086957 million shares in the past 12 months
Medicenna Therapeutics Corp. ( MDNA ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Medicenna Therapeutics Corp. ( MDNA ) Interest-bearing Debt ($MM) as of last quarter is 0
Medicenna Therapeutics Corp. ( MDNA ) Annual Working Capital Investments ($MM) are -1
Medicenna Therapeutics Corp. ( MDNA ) Book Value ($MM) as of last quarter is 17
Medicenna Therapeutics Corp. ( MDNA ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Medicenna Therapeutics Corp. ( MDNA ) has 19 million in cash on hand as of last quarter
Medicenna Therapeutics Corp. ( MDNA ) has 2 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Medicenna Therapeutics Corp. ( MDNA ) has 69 common shares outstanding as of last quarter
Medicenna Therapeutics Corp. ( MDNA ) has 0 million USD of preferred stock value
Academic Scores:
Medicenna Therapeutics Corp. ( MDNA ) Altman Z-Score is -2.06 as of last quarter
Medicenna Therapeutics Corp. ( MDNA ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Medicenna Therapeutics Corp. ( MDNA ) largest shareholder is Tocqueville Asset Management L.P. owning 79000 shares at 0.02 ($MM) value
(an insider) shares of Medicenna Therapeutics Corp. ( MDNA ) for the amount of $ on
17.51% of Medicenna Therapeutics Corp. ( MDNA ) is held by insiders, and 10.04% is held by institutions
Medicenna Therapeutics Corp. ( MDNA ) went public on 2001-08-27
Other Medicenna Therapeutics Corp. ( MDNA ) financial metrics:
FCF:-10.71
Unlevered Free Cash Flow:0.00
EPS:-0.16
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-64.69
Beta:2.21
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Medicenna Therapeutics Corp. ( MDNA ) :
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.